Researchers Establish Link Between Chromium VI and Stomach Cancer via a Meta-Analysis of Epidemiological Evidence
the Cancer Therapy Advisor take:
It has been previously established that there is a causal link between chromium VI (hexavalent chromium) and lung cancer, but the relationship between chromium VI and gastrointestinal cancer has not been well established.
Researchers from the California Environmental Protection Agency and Kaiser Permanente developed a study to identify whether or not the established human epidemiological research on chromium VI that has occupationally inhaled supports their hypothesis that there is a link between chromium VI and stomach cancer in humans.
The researchers conducted a thorough search and review of literature and studies and summarized the content of the current epidemiological findings related to inhaled chromium VI and stomach cancer via a meta-analysis. The meta analysis also explored heterogeneity sources.
The researchers found 76 individual relative risk estimates and 56 cohort and case-control studies related to an individual’s exposure to chromium VI and incidence of stomach cancer. The summary relative risk for the combination of all studies was 1.27 (95% confidence interval [CI] 1.18 to 1.38).
When the researchers analysis was restricted to studies that only looked at the increase in risk of lung cancer the summary relative risk was higher, 1.41 (95% CI 1.18 to 1.69). The results of this study indicate that chromium VI is related to stomach cancer in humans, which was already established in studies of rodents.
Researchers studied link between chromium VI and stomach cancer in humans.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer